Lung Cancer Surgery Market By Type of Surgery (Lobectomy, Pneumonectomy, Segmentectomy, Wedge Resection), By Procedure Type (Open Surgery, Minimally Invasive Surgery, Robotic Surgery), By End-User (Hospitals, Surgical Centers, Cancer Research Institutes), and By Region; Global Insights & Forecast (2023 ? 2030)

As per Intent Market Research, the Lung Cancer Surgery Market was valued at USD 5.7 Billion in 2024-e and will surpass USD 7.9 Billion by 2030; growing at a CAGR of 5.5% during 2025-2030.

The lung cancer surgery market is driven by the growing incidence of lung cancer worldwide, alongside advancements in surgical technologies and techniques. Surgical resection remains one of the most effective treatments for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), particularly when diagnosed at an early stage. As the market evolves, there is an increasing shift towards minimally invasive surgical techniques, which offer benefits such as reduced recovery times, shorter hospital stays, and lower complication rates. This shift in surgical approach, coupled with the growing adoption of robotic-assisted surgery, is shaping the future of lung cancer treatment. This market is poised for growth, supported by the rising number of patients diagnosed with lung cancer and increasing healthcare spending on advanced surgical procedures.

Lobectomy Segment Is Largest Owing to Its Effectiveness

Lobectomy is the most common surgical procedure for lung cancer, particularly in cases where the cancer is localized to one of the lung's lobes. This procedure involves the removal of an entire lung lobe and is considered the gold standard for treating early-stage non-small cell lung cancer (NSCLC). As the largest segment in the lung cancer surgery market, lobectomy remains the most preferred surgical option due to its proven effectiveness in removing tumors while preserving lung function. Given that lung cancer is often detected at an operable stage, the demand for lobectomies continues to rise, especially in regions with advanced healthcare systems.

The growth of this segment is supported by advancements in surgical techniques, making lobectomy less invasive and more precise. The increasing use of video-assisted thoracoscopic surgery (VATS) and robotic surgery has further enhanced the safety and recovery time associated with lobectomies. As a result, patients are benefiting from shorter hospital stays and reduced post-surgical complications, driving the continued dominance of lobectomy in lung cancer treatment.

Minimally Invasive Surgery (MIS) Is Fastest Growing Owing to Technological Advancements

Minimally invasive surgery (MIS) is the fastest-growing procedure type in lung cancer surgery, primarily due to technological advancements and its proven advantages over traditional open surgery. MIS techniques, such as video-assisted thoracoscopic surgery (VATS), allow surgeons to remove tumors with smaller incisions, which reduces blood loss, minimizes pain, and shortens recovery times. As a result, patients experience faster recovery and are able to resume normal activities sooner compared to open surgery.

The growing popularity of MIS can be attributed to the increasing adoption of robotic-assisted surgery systems, such as the da Vinci Surgical System. These systems enhance precision and control, allowing for more complex surgeries to be performed with minimal invasiveness. Furthermore, as the global focus shifts toward improving patient outcomes and reducing healthcare costs, MIS has become a preferred option in lung cancer surgery, leading to its rapid growth in the market.

Hospitals Are Largest End-User Due to High Surgery Volume

Hospitals remain the largest end-user segment in the lung cancer surgery market, primarily due to their comprehensive capabilities in handling complex surgical procedures and their ability to provide post-surgical care. Hospitals have the necessary infrastructure, skilled personnel, and advanced surgical equipment required for lung cancer surgeries. Additionally, hospitals serve as key centers for diagnosis, surgery, and post-operative care, making them the central hub for lung cancer treatment.

Hospitals also benefit from their ability to perform a wide range of surgeries, including open surgeries, minimally invasive procedures, and robotic-assisted surgeries, depending on the patient's needs. The large volume of surgeries performed in hospitals, alongside the growing adoption of new technologies, ensures that hospitals will continue to dominate this segment for the foreseeable future.

North America Is Largest Market Owing to Advanced Healthcare Infrastructure

North America holds the largest share of the global lung cancer surgery market, driven by its advanced healthcare infrastructure, high healthcare spending, and widespread access to cutting-edge surgical technologies. The United States, in particular, is a major contributor to the market, with a high prevalence of lung cancer and significant investments in medical research and innovation. North American hospitals are equipped with the latest technologies, including robotic surgical systems and minimally invasive techniques, which are increasingly being adopted for lung cancer surgeries.

Moreover, the region benefits from a high level of awareness regarding lung cancer and the available treatment options, which encourages early detection and timely intervention. This has helped North America maintain its leadership in the market, with hospitals and surgical centers offering comprehensive lung cancer care that includes surgery, chemotherapy, and radiation therapy.

Competitive Landscape and Leading Companies

The lung cancer surgery market is characterized by the presence of several prominent players offering a range of surgical systems, technologies, and services. Leading companies in the market include Medtronic, Intuitive Surgical, Johnson & Johnson, and Zimmer Biomet, all of which have invested significantly in the development of robotic-assisted and minimally invasive surgical technologies. Medtronic and Intuitive Surgical, in particular, are at the forefront of robotic surgery innovations, with their robotic-assisted systems being widely adopted in hospitals and surgical centers globally.

Other key players like Stryker Corporation, Boston Scientific, and Olympus Corporation also play a significant role in the market by providing advanced surgical instruments and imaging systems that support lung cancer surgeries. The competitive landscape is marked by continuous innovation, with companies focusing on enhancing the precision, safety, and efficiency of lung cancer surgeries. As the demand for minimally invasive procedures increases, these companies are expected to continue driving technological advancements to improve patient outcomes and expand their market presence.

Recent Developments:

• Medtronic announced the launch of its Hugo™ robotic-assisted surgery platform, enhancing precision in lung cancer surgeries with advanced technology and improved surgical outcomes.
• Intuitive Surgical introduced new features for its da Vinci™ robotic surgery system, aimed at improving lung cancer resection with greater precision and fewer complications.
• Boston Scientific's new self-expanding stent designed for airway management in lung cancer patients received FDA approval, expanding its offering in the lung cancer treatment market.
• Johnson & Johnson's medical devices division announced a major investment in the development of robotic-assisted surgery technologies, enhancing its presence in the lung cancer surgery market.
• Zimmer Biomet entered a partnership with leading cancer centers to integrate advanced surgical tools and robotic systems into lung cancer surgeries, improving patient outcomes and recovery times.

List of Leading Companies:

• Medtronic
• Intuitive Surgical
• Johnson & Johnson
• Stryker Corporation
• Zimmer Biomet
• Boston Scientific
• Smith & Nephew
• Olympus Corporation
• Karl Storz GmbH & Co. KG
• Ethicon (Johnson & Johnson)
• CONMED Corporation
• Hansen Medical
• Johnson & Johnson Medical Devices
• Karl Storz GmbH & Co. KG
• Mazor Robotics

Report Scope: